Early intracardiac thrombosis in preterm infants and thrombolysis with recombinant tissue type plasminogen activator

OBJECTIVES To determine the incidence of catheter related thrombosis and to test the efficacy of recombinant tissue type plasminogen activator (rt-PA) in preterm infants. STUDY DESIGN From January 1995 to December 1998, echocardiography was performed in the first few days of life in 76 very low birthweight (⩽ 1500 g) infants out of a total of 147 having an umbilical catheter placed. When intracardiac thrombosis was diagnosed, rt-PA infusion was performed. RESULTS Four infants (5%) developed an intracardiac thrombosis during the first few days of life. In three of them, rt-PA at a dose of 0.4–0.5 mg/kg in a 20–30 minute bolus led to dissolution of the clot. One patient received a three hour infusion after the bolus, at a dose of 0.1 mg/kg/h, with resolution of the thrombus. No systemic effects were observed after rt-PA infusion. CONCLUSIONS Early thrombosis may occur as a complication of umbilical catheterisation in preterm infants; early echocardiographic detection of this disorder allows complete, safe, and rapid lysis with rt-PA.

[1]  R. Hetzer,et al.  Surgical emergency embolectomy for the treatment of fulminant pulmonary embolism in a preterm infant. , 1997, Journal of pediatric surgery.

[2]  H. Ruder,et al.  Successful systemic low-dose lysis of a caval thrombus by rt-PA in a neonate with congenital nephrotic syndrome. , 1997, Journal of pediatric hematology/oncology.

[3]  P. Daoud,et al.  Thrombose artérielle néonatale spontanée traitée par activateur tissulaire du plasminogène , 1997 .

[4]  T. Krummel,et al.  Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy. , 1993, Journal of pediatric surgery.

[5]  T. Santulli,et al.  Central Venous Line Thrombosis in Premature Infants: A Case Management and Literature Review , 1993, American journal of perinatology.

[6]  J. Acker,et al.  Intracardiac thrombus formation with rapidly progressive heart failure in the neonate: treatment with tissue type plasminogen activator. , 1992, Archives of disease in childhood.

[7]  G. Koren,et al.  Tissue plasminogen activator for the treatment of thromboembolism in infants and children. , 1991, The Journal of pediatrics.

[8]  B. Anderson,et al.  Caval Thrombolysis in Neonates Using Low Doses of Recombinant Human Tissue-Type Plasminogen Activator , 1991, Anaesthesia and intensive care.

[9]  W. Drummond,et al.  Successful treatment of neonatal aortic thrombosis with tissue plasminogen activator. , 1990, The Journal of pediatrics.

[10]  R. W. Holden,et al.  Plasminogen activators: pharmacology and therapy. , 1990, Radiology.

[11]  R. Verhaeghe,et al.  Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis. , 1989, Thrombosis research.

[12]  G. Pongiglione,et al.  Right atrial thrombosis in two premature infants: successful treatment with urokinase and heparin. , 1986, European heart journal.

[13]  A. Connors,et al.  Thrombosis and infection complicating central venous catheterization in neonates. , 1986, Journal of pediatric surgery.

[14]  H. Mactier,et al.  Central venous catheterisation in very low birthweight infants. , 1986, Archives of disease in childhood.

[15]  L. Steinfeld,et al.  Intracardiac thrombi complicating central total parenteral nutrition: resolution without surgery or thrombolysis. , 1986, The Journal of pediatrics.

[16]  B. Schmidt,et al.  Thrombotic disease in newborn infants. , 1984, Clinics in perinatology.

[17]  A. Rousset,et al.  [Spontaneous neonatal arterial thrombosis treated with tissue plasminogen activator]. , 1997, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[18]  D. De Wolf,et al.  Diagnosis and Management of Catheter-Related Infected Intracardiac Thrombosis in Premature Infants , 1993, American journal of perinatology.

[19]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[20]  A. Jaffe,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. , 1988, Journal of the American College of Cardiology.